Sun et al. elucidated the synergistic oncogenic interaction between CDKN2A-p16 deletion and KRASG12D activation, which significantly accelerates the progression from Barrett’s esophagus to dysplasia and activates multiple oncogenic pathways, including MAPK [25]. Here, CDKN2A is linked to esophageal adenocarcinoma.